| Popis: |
Most patients with mild cognitive impairment (MCI) treated with cerebrolysin have mainly beneficial outcomes, but some of them develop dementia, hence, the study targeted individual prediction of the treatment efficacy and dementia risks assessment, revelation of the most informative scorings in clinical tests. Patients with amnestic mild cognitive impairment (aMCI) (n=53) were regularly intravenously treated with cerebrolysin for three years and tested using neurocognitive and clinical psychiatric tests; the data (scores) was analyzed using non-parametric statistics, cluster analysis, and linear discriminant analysis (LDA). Combining the mathematical methods has enabled prognosis of cognitive decline to dementia in the treated patients basing on their initial scorings in tests. A “dementia risk group” with fast cognitive decline (i.e. low efficacy of the treatment) has been revealed. The tests are ranked according with their predictive values. Separation of “risk group” (n=8) is reasonable, consisting of patients with dementia outcome (n=3) together with those patients (n=5) who is not diagnosed as demented after the treatment, but closely related to demented patients in their scorings. Initially lower scorings in Mattis Dementia Rating Scale Memory subtest, Mini-Mental State Examination, 10 word list immediate recall, and Frontal Assessment Battery tests, and relatively higher scorings in Hamilton Depression Rating Scale may suggest poor prognosis for patients with MCI treated with cerebrolysin. |
